Inhibikase Therapeutics is a clinical-stage company developing IKT-001, a once-daily pill that becomes imatinib in the blood, for pulmonary arterial hypertension; it is not approved.
Inhibikase's case rests on IKT-001, an imatinib prodrug designed to reduce the gut side effects that limited imatinib in pulmonary arterial hypertension. IKT-001 has only healthy-volunteer data, matching imatinib exposure without dose-dependent GI side effects, and Phase 3 IMPROVE-PAH dosed its first patient in April 2026, with no readout dates given. Cash of $159.0 million plus $50 million from RA Capital funds operations through Part B data only if its Series A and B warrants are exercised in full.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Part A shows a clear cut in pulmonary vascular resistance
Does IKT-001 cut pulmonary vascular resistance versus placebo, in line with imatinib, with better tolerability?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Inhibikase's IKT-001, an imatinib prodrug, is enrolling the two-part IMPROVE-PAH Phase 3 in pulmonary arterial hypertension; it must deliver imatinib's benefit with better tolerability
IKT-001 enters a crowded PAH market with a Phase 3 trial that must demonstrate PVR and 6MWD benefit against established standard-of-care backbones
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung and respiratory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.